Novozymes (NVZMY)
(Delayed Data from OTC)
$55.35 USD
-0.31 (-0.56%)
Updated Apr 25, 2024 03:59 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Novozymes AS falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,599 | 2,486 | 2,379 | 2,147 | 2,155 |
Cost Of Goods | 1,187 | 1,129 | 1,007 | 944 | 962 |
Gross Profit | 1,412 | 1,356 | 1,372 | 1,203 | 1,192 |
Selling & Adminstrative & Depr. & Amort Expenses | 834 | 710 | 734 | 644 | 587 |
Income After Depreciation & Amortization | 577 | 646 | 638 | 559 | 605 |
Non-Operating Income | 38 | 74 | 27 | 3 | 16 |
Interest Expense | 48 | 75 | 40 | 23 | 52 |
Pretax Income | 568 | 645 | 624 | 539 | 569 |
Income Taxes | 126 | 123 | 124 | 106 | 97 |
Minority Interest | 2 | 1 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 441 | 522 | 500 | 433 | 473 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 439 | 521 | 501 | 433 | 473 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 577 | 646 | 638 | 559 | 605 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 577 | 646 | 638 | 559 | 605 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 279.32 | 278.70 | 280.14 | 282.00 | 286.56 |
Diluted EPS Before Non-Recurring Items | 1.58 | 1.87 | 1.79 | 1.53 | 1.65 |
Diluted Net EPS (GAAP) | 1.58 | 1.87 | 1.79 | 1.54 | 1.65 |
Fiscal Year end for Novozymes AS falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 666.08 | 650.58 | 616.10 | 666.17 |
Cost Of Goods | NA | 306.53 | 300.47 | 274.81 | 305.49 |
Gross Profit | NA | 359.55 | 350.11 | 341.29 | 360.68 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 221.24 | 200.90 | 214.91 | 197.27 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 138.31 | 149.21 | 126.38 | 163.41 |
Non-Operating Income | NA | 20.51 | 18.40 | 0.15 | -0.72 |
Interest Expense | NA | 25.30 | 0.00 | 9.93 | 12.82 |
Pretax Income | NA | 133.53 | 167.61 | 116.59 | 149.86 |
Income Taxes | NA | 33.03 | 31.97 | 26.88 | 34.44 |
Minority Interest | NA | -0.42 | -1.02 | 1.17 | 2.45 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 100.50 | 135.63 | 89.71 | 115.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 100.92 | 136.66 | 88.54 | 112.97 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 276.89 | 277.70 | 277.90 | 277.80 |
Diluted EPS Before Non-Recurring Items | NA | 0.36 | 0.49 | 0.32 | 0.41 |
Diluted Net EPS (GAAP) | NA | 0.36 | 0.49 | 0.32 | 0.41 |